Skip to main content
Fig. 2 | BMC Veterinary Research

Fig. 2

From: Cytoplasmic glycoengineering of Apx toxin fragments in the development of Actinobacillus pleuropneumoniae glycoconjugate vaccines

Fig. 2

Expression and solubility of ApxIA peptide fragments. a- Schematic representation of the domain architecture of ApxIA. b- The ‘hydrophobic’ domain (D1) and Ca2+-binding domain (D3) of ApxIA were recombinantly expressed in E. coli, lysed and soluble and insoluble fractions were resolved by SDS-PAGE. c- Expression and solubility of ApxIA fragments immunoblot detected using an anti-6xHis (green) antibody. Lane 1: Ladder; lane 2: E. coli expressing ApxIAD3 (soluble); lane 3: ApxIAD1; lane 4: ApxIAD2; lane 5: MBP-ApxIAD1 fusion; lane 6: MBPNlinker-ApxIAD1 fusion; lane 7: ApxIAD3 Ni-NTA affinity purified; lane 8 ApxIAD3 (whole cell lysate); lane 9: ApxIAD1; lane 10: ApxIAD2; lane 11: MBP-ApxIAD1 fusion; lane 12: MBPNlinker-ApxIAD1 fusion

Back to article page

BMC Veterinary Research

ISSN: 1746-6148

Contact us